Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) Net Income towards Common Stockholders: 2020-2025

Historic Net Income towards Common Stockholders for Pharming Group N.V (PHAR) over the last 4 years, with Sep 2025 value amounting to $90.2 million.

  • Pharming Group N.V's Net Income towards Common Stockholders rose 1255.41% to $90.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.8 million, marking a year-over-year increase of 495.63%. This contributed to the annual value of -$12.0 million for FY2024, which is 283.16% down from last year.
  • Per Pharming Group N.V's latest filing, its Net Income towards Common Stockholders stood at $90.2 million for Q3 2025, which was up 856.29% from $9.4 million recorded in Q2 2025.
  • Pharming Group N.V's 5-year Net Income towards Common Stockholders high stood at $90.2 million for Q3 2025, and its period low was -$25.7 million during Q3 2021.
  • Its 3-year average for Net Income towards Common Stockholders is $5.1 million, with a median of $3.4 million in 2023.
  • Per our database at Business Quant, Pharming Group N.V's Net Income towards Common Stockholders skyrocketed by 29,235.91% in 2022 and then slumped by 463.64% in 2023.
  • Quarterly analysis of 5 years shows Pharming Group N.V's Net Income towards Common Stockholders stood at $5.7 million in 2021, then plummeted by 132.35% to -$1.8 million in 2022, then skyrocketed by 375.83% to $5.1 million in 2023, then rose by 28.20% to $6.5 million in 2024, then soared by 1,255.41% to $90.2 million in 2025.
  • Its Net Income towards Common Stockholders was $90.2 million in Q3 2025, compared to $9.4 million in Q2 2025 and $6.5 million in Q4 2024.